RLYB Historical PE Ratio Notes

— Rallybio (ticker symbol RLYB) is a clinical-stage biotechnology company focused on discovering & developing novel therapies for patients with severe & rare diseases, particularly those with high unmet medical needs. The company's pipeline includes candidates for immune & hematologic disorders, such as rare blood diseases & maternal-fetal conditions. Since RLYB is still in the development stage, its revenue generation is minimal or nonexistent, & expenses are largely tied to research & development. This directly impacts its historical price-earnings (PE) ratio: as earnings have often been negative or negligible, standard PE ratios may not be meaningful, may not be calculable at all (if earnings are negative), or can appear extremely high due to a low denominator. When you review RLYB’s historical charts, you’ll likely notice periods with a zero, undefined, or very high PE ratio—this reflects the nature of biotech firms with early-stage pipelines that have yet to reach commercial sales. As a result, investors have traditionally valued such companies more on future potential & progress in clinical trials than on current earnings, which needs to be kept in mind when interpreting historical valuation figures.

On this page we presented the Rallybio Historical PE Ratio information for Rallybio' stock. The average RLYB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average RLYB historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this RLYB historical PE result, against the recent PE: when this page was posted on 6/1/2026, the most recent closing price for RLYB had been 16.87, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on RLYB or any other given stock, valuation analysis for RLYB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Rallybio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for RLYB. Thanks for visiting, and the next time you need to research RLYB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.